_P2, _psyeBotie disorders and a~tipsye#oticx $255 larger cohort of schizophrenia patients are needed in order to substantiate our findings. • Weight gain in Korean schizophrenia Jnpat|ents: A comparison of risperidone and olanzapine H. Kim, K.J. Lee, S.K. Lee, Y.C. Chung. 7lsan _paikHospital, Inje University,, Neuropsyehiatry, Goyang @eonggi, ~epuNie of Korea Weight gain is a frequent side effect of antipsychotic medication which has serious implications for a patient's health and well be- ing. Weight gain associated with pychotropic medications has been attributed to an interference with serotonergic neurotrnasmission. Since atypical antip~chotic agents interfere with serotonergic neurotransmission, they can potentially influence body weight. The aim of this prospective study was to evaluate the effect of rirperidone and olanzapine treatment on body weight in Ko- rean schizophrenia inpatients. DSM-IV-defined schizophrenia in- patients who have newly started treatment with either risperidone or olanzapine were consecutively enrolled. A subset of medication group was selected to match for age and sex in a case-control design. Each patient gave informed consent for the research in this study. To control other factors like ethnic group, onset of illness and activity level that possibly have influence on body weight, the inclusion criteria for this study included Korean first onset schizophrenia inpatients. Body weight was obtained in kilograms and height in meters at baseline and at en@oint. Changes of mean body weight, and body mass index [BIVE = weight (kg)/ height (m) squared] were compared between medication groups following 8 weeks of treatment. The meanq-SD risperidone dose was 4.94-1.8 mg/day in risperidone group (N=37) and the mean 4-SD olanzapine dose was 12.74-,1.9 mg/day in olanzapine group (N=25) at week 8. 89.2% of risperidone group and 80.0% of olanzapine group had gained weight. Only 5.4% of risperidone group and 20.0% of olanzapine group had lost weight. In another 5.4% of risperidone group showed no body weight change. There was no significant difference in mean body weight changes after 8 weeks (3.804-3.54 kg in rirperidone group vs 5.064-2.65 kg in olartzapine group, p=0.135). Mean changes in BMI(1.724-1.69 kg/square meter in risperidone group vs 1.874-0.82 kg/square meter in olanzapine group, p=0.785) and in total serum cholezterol level (16.94-32.4 mg/dl in rirperidone group vs 21.94-27.8 mg/dl in olanzapine group, p=0.682) between two groups were also not significant. In this study, treatment with risperidone or olanzapine was associated with significant weight gain in Korean inpatients with schizophrenia. But there was no siginificant difference be- tween groups. As a whole, olazapine group showed a tendency to gain more weight than risperidone group. However, in olanzapine group (20.0%), more patients had lost weight than in risperidone group (9.4%). It can be hypothesized that some schizophrenia patients are vulnerable to weight gain with olanzapine medica- tion. Weight gain may reduce compliance with medication, so further studies of interventions designed to control weight gain in schizophrenia due to a side effect of medication are warranted. • T h e clinical status of neuroleptic na'ive patients with schizophrenia following monotherapy with olanzapine, risperidone or typical antipsychotics: A 12-month analysis T. Treuer I , Q. G~I2, L. Raducan 3 , S. Rudzianskieng 1, A. Szulc 5, J. Pecenak 6 , D. Logozar PerkoviJ, J. Leadbetter 8 , J. O'Makoney 8 . 1Eli Lilly, Ges.m.b.H, (Yinical 8esearc~ Neuroscience, ~enna, Austria; 2Psychiatry Outpatient Clinic. Department of Psychiatry, Mezdt~r, Hungary; S_prioate Clinic, 133 Stefan eel Mare St, Department of _psychiatry, Constants. ~omania; 4 Silainiu Men~al Health Center, Department of _Psyc~iat~ Kaunas, Lithuania; SMedical Academy, Department of _Psychiatry, Choroszoz, _Poland; 6 Unioers#y Hospital Dratislaua, Department of_psychiatry, Bratigaoa, Slooakia; 7 _psiJ~iatr~cnaBolniea ©rmoz, Department of_psychiatry, Ormoz, Slooenia; gEli Lilly Australia _pry Limited, Clinical Outeome~ and Nesearoh Institute. Sydney, Australia Objective: To compare the Clinical @lobal Impression- Schizophrenia scale (CGI-SCH) scores, the incidence of ex- trapyramidal symptoms (EPS), and medication use in patients with schizophrenia who have undergone antipg, chotic treatment for the first time (neuroleptic naive), and were prescribed monotherapy with olanzapine, risperidone, or typical antipsychotics, Metheds-" The Intercontinental Schizophrenia Outpatient Health Outcomes study (IC-SOKO) is a 3-year, prorpective, ob- servational study of health outcomes associated with antipsychotic medication therapy in outpatients treated for schizophrenia. The intercontinental sample population (N=7658 at baseline) from Africa, the Middle East, Asia, Central and Eastern Europe, and Latin America, were oulpatients, > 18 years of age, who presented to a p~ychiatrist in the normal course of care for the treatment of schizophrenia with either olanzapine or non-olanzapine antipsy- chotics. A subgroup analysis of neuroleptic nai've patients from the IC-SOHO patient data was performed following 12 months of treatment. For the purpose of this subgroup analysis, only those patients who remained on monotherapy with olanzapine, risperidone, or typical antip~ychotics for at least 3 months were in- cluded. Sample sizes decreased with time as patients changed an- tipsychotic medication. Patients prescribed th,pical antipsychotics (typicals) were grouped due to the limited sample size. Number of neuroleptie naive patients vane remained on menotherapy Olanzapine Risperidone Typicals 3 Months 306 112 45 12 Months 232 75 28 Measures presented include a modified Clinical Global Impressions scale (CGI-SCH), the incidence of EPS, and medication use. Results: Neuroleptic nffive patients who remained on monother- spy at 12 months had a greater improvement %r all CGT-SCH symptom domains (overall, positive, negative, depressive, and cognitive) if treated with olanzapine compared with thDicals (p~<0.002). Risperidone was superior to typicals for changes in positive and negative symptoms only (p<.05). Although olanza- pine was comparable to risperidone for improvement in positive symptoms, it was superior for the treatment of overall, negative, depressive, and cognitive symptoms (p<.05). During 12 months of antipsychotic monotherapy, overall CGI-SCH scores worsened in 13.,1% of patients treated with olanzapine, 23.5% of those treated